A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1059 participants.
Also called NCT05205499
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,059 participants
- Registry
-
NCT05205499
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05205499. Allocation not applicable; no masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2024-07-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
- Acronym
- IRONMAN-III
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
- Lead sponsor
- Biotyx Medical (Shenzhen) Co., Ltd.
Record details
- Record id
cardio:ct-nct05205499- Content hash
7edb5cfdf7bb7b6b18dfe7f6e25df247ffdf31e291b7781b4231c8e5e70fcd6f